NYSE - Delayed Quote USD

Bristol-Myers Squibb Company (BMY)

48.30

+0.46

(+0.96%)

At close: April 18 at 4:00 PM EDT

48.30

0.00

(0.00%)

After hours: April 18 at 7:56 PM EDT

Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 17 hours ago

CELG-RT

BMRN
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

These income stocks look like good options at current levels.

Motley Fool yesterday

CELG-RT

NVS
-0.55%
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors

Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.

Zacks 3 days ago

CELG-RT
In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions

Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence...

Simply Wall St. 3 days ago

BMY
+0.96%
CELG-RT
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?

Motley Fool 3 days ago

CELG-RT

^GSPC
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

Zacks 6 days ago

AMLX

MRNA

CELG-RT
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024

Many investors are hearing that we are in a stock picker’s market. If that’s the case, then why not take your lead from Warren Buffett? After all, Buffett is one of the world’s best stock pickers. What do you know about these stocks? If you follow the Buffett playbook, then these stocks will have wide moats that protect them from competition, they are financially sound companies, and they have a proven history of returning capital to investors in the form of dividends and share buybacks. Another

InvestorPlace 6 days ago

V

CELG-RT

OXY-WS
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF’s (NYSEARCA:XBI) 25% bump in value over the past six months, outpacing broader market gains. Moreover, with the impending interest rates cuts, it might be an ideal time to scoop the top biotech players on the dip. Interest in the biotech sphere will continue to grow on the back of several factors, including revolutionary new treatmen

InvestorPlace 7 days ago

MRNA

CELG-RT

VKTX
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Zacks 7 days ago

ALXO

ROG.SW

NRIX
Building a Better Future: Bristol Myers Squibb 2023 ESG Report

NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company: At Bristol Myers Squibb, our vision is to transform patients' lives through science Originally published on Bristol Myers Squibb News & Perspectives Since 1887, BMS has ...

ACCESSWIRE 7 days ago

BMY
+0.96%
CELG-RT
A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 7 days ago

BMY
+0.96%
CELG-RT
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.

Zacks 8 days ago

MRNA

AMLX

CELG-RT
The Pharmaceutical Industry Finds Itself At A Historical Crossroads

Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk. The expiration of patents for one or more leading branded products for a company means opening the door to competitors to sell copycats of those drugs, often at a competitive price. But, as always, pharmaceutical companies do their best

Benzinga 8 days ago

JNJ
+0.67%
CELG-RT

PFE
-0.12%
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist

These reliable dividend payers offer yields of 3.3% and better at recent prices.

Motley Fool 8 days ago

CELG-RT

CLX
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.

Zacks 9 days ago

CELG-RT
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Zacks 9 days ago

CELG-RT
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

Motley Fool 9 days ago

ABBV
+0.25%
JNJ
+0.67%
CELG-RT
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation

Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer. With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median progression-free survival of 6.9 months, and median overall survival of 15.9 months

Benzinga 10 days ago

CELG-RT
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.

Zacks 10 days ago

CELG-RT
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

PRINCETON, N.J., April 08, 2024--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.....

Business Wire 10 days ago

BMY
+0.96%
CELG-RT

Performance Overview

Return	BMY	S&P 500
YTD	-3.67%	+5.06%
1-Year	-28.65%	+20.71%
3-Year	-18.11%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company (BMY)

Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors

In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions

Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

Building a Better Future: Bristol Myers Squibb 2023 ESG Report

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

The Pharmaceutical Industry Finds Itself At A Historical Crossroads

2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Performance Overview